Evidence map›Paper›PMID 39071275›Full record

ArticlebioRxiv : the preprint server for biology2024

Small molecule FICD inhibitors suppress endogenous and pathologic FICD-mediated protein AMPylation.

Bhaskar K Chatterjee, Maroof Alam, Arghya Chakravorty, Shannon M Lacy, Jason Rech, Charles L Brooks, Peter D Arvan, Matthias C Truttmann

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Bhaskar K ChatterjeeDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Maroof AlamDepartment of Internal Medicine- Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, 48109, USA.
Arghya ChakravortyDepartment of Chemistry, University of Michigan, Ann Arbor, MI, 48109, USA.
Shannon M LacyDepartment of Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI, 48109, USA.
Jason RechVahlteich Medicinal Chemistry Core, University of Michigan, Ann Arbor, MI, 48109, USA.
Charles L BrooksDepartment of Internal Medicine- Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-8149-5417
Peter D ArvanDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Matthias C TruttmannDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.

Funding

Conserved regulation of proteostasis by post-translational protein AMPylationR35GM142561 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Matthias Christof Truttmann · 2021 to 2026
$2.8M
NIGMS NIH HHS R35 GM142561
6 · The paper itself

Abstract

The AMP transferase, FICD, is an emerging drug target finetuning stress signaling in the endoplasmic reticulum (ER). FICD is a bi-functional enzyme, catalyzing both AMP addition (AMPylation) and removal (deAMPylation) from the ER resident chaperone BiP/GRP78. Despite increasing evidence linking excessive BiP/GRP78 AMPylation to human diseases, small molecules to inhibit pathogenic FICD variants are lacking. Using an

Indexed as

AMPylationBiPcytotoxicityFICDhigh-throughput screenproinsulinsmall-molecule

Identifiers

PMID39071275
PMCPMC11275912

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.